Kymriah (tisagenlecleucel) - The Lone Wolf of Cryopreserved CSM
I was chatting with an AI the other day about approved cell-based therapies that use cryopreserved starting material. The AI initially gave an answer that made me skeptical. I dug deeper and decided to publish this here as an example of where our existing cellular supply chain may be misunderstood.
Revisiting cryopreservation in therapies
AI: Okay, so cryopreservation typically happens after activation or transduction in some therapies, but not necessarily in licensed products. I should separate fresh vs. frozen CSM and mention that some development work shows feasibility. For TILs, the CSM is tumor tissue, and they cryopreserve it before expansion. For cord blood, CSM is the final product, but no gene introduction. For CAR-T, gene introduction is transduction, so I need to check if cryopreservation happens before that. I’ll structure the response with clarified definitions, re-analysis per product, and a direct answer. You’re absolutely right to draw that line—most public discussions blur CSM vs DS/DP, and that really matters for what you’re trying to map.
Let’s reset with your definitions and then re-walk the products.
1. Working definitions (per your clarification)
Cellular starting material (CSM):
Apheresis (or analogous harvested cells/tissue) before any gene introduction or ex vivo genetic modification.
For CAR‑T: leukapheresis product prior to activation/transduction.
For TIL: tumor/tumor digest prior to ex vivo expansion (no gene step, but still “starting material”).Drug substance (DS):
Genetically modified and/or expanded cells before final formulation/fill/finish.Drug product (DP):
Final formulated cell therapy in its clinical presentation (e.g., cryopreserved infusion bag).
Your rule:
If no cryopreserved CSM is used prior to gene introduction, then that DP does not “use cryopreserved CSM,” even if DS/DP are cryopreserved.
I’ll stick to that.
2. Re-analysis of the six autologous CAR‑T products
Public FDA/EMA documents and sponsor materials are generally explicit about DP being cryopreserved, but much less explicit about CSM (apheresis) being cryopreserved before gene introduction. Where the BLA/SmPC is silent, we should not assume frozen CSM is part of the licensed process.
Kymriah (tisagenlecleucel)
CSM: Autologous leukapheresis.
Public evidence: Describes apheresis collection and shipment to the manufacturing site; public docs emphasize cryopreserved DP, not cryopreserved apheresis.
Conclusion (under your definition):
CSM cryopreserved prior to gene introduction? Not clearly supported in public regulatory docs.
We cannot confidently classify Kymriah as using cryopreserved CSM in the licensed process.
Yescarta (axicabtagene ciloleucel)
CSM: Autologous leukapheresis.
Public evidence: FDA/EMA documents describe fresh apheresis collection and shipment; cryopreservation is clearly specified for DP.
Conclusion:
CSM cryopreserved prior to gene introduction? Not supported by public regulatory text.
No solid basis to claim cryopreserved CSM in the licensed process.
Tecartus (brexucabtagene autoleucel)
CSM: Autologous leukapheresis.
Public evidence: Similar to Yescarta—clear that DP is cryopreserved, but CSM is described as collected and shipped, not explicitly frozen pre‑transduction.
Conclusion:
CSM cryopreserved prior to gene introduction? Not demonstrated in public docs.
Should not be counted as using cryopreserved CSM on current evidence.
Breyanzi (lisocabtagene maraleucel)
CSM: Autologous leukapheresis, later separated into CD4/CD8 fractions.
Public evidence: Strong detail on cryopreserved CD4/CD8 DS/DP fractions, but again, apheresis is described as the starting material, not explicitly cryopreserved before gene modification.
Conclusion:
CSM cryopreserved prior to gene introduction? Not clearly documented.
Only DS/DP are clearly cryopreserved; CSM status remains “not evidenced as frozen”.
Abecma (idecabtagene vicleucel)
CSM: Autologous leukapheresis.
Public evidence: PI and reviews emphasize cryopreserved DP; CSM is described as leukapheresis, with no explicit statement that it is cryopreserved prior to transduction.
Conclusion:
CSM cryopreserved prior to gene introduction? Not supported by public regulatory language.
Should not be classified as using cryopreserved CSM.
Carvykti (ciltacabtagene autoleucel)
CSM: Autologous leukapheresis.
Public evidence: Clear that DP is cryopreserved; CSM is leukapheresis, again without explicit pre‑transduction cryopreservation in public docs.
Conclusion:
CSM cryopreserved prior to gene introduction? Not clearly documented.
Only DS/DP are clearly cryopreserved.
3. Where cryopreserved CSM is clearly used
If we apply your strict definition, and only count cases where the harvested cellular material is cryopreserved before any gene introduction or ex vivo manipulation, the picture changes:
Autologous CAR‑T (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti):
Regulatory docs clearly support cryopreserved DS/DP.
They do not clearly document cryopreserved CSM (apheresis) as part of the licensed process.
Some development papers and platform work show feasibility of frozen leukopaks, but that’s not the same as a licensed, required CSM step.
Autologous TIL (Amtagvi):
CSM: Tumor/tumor digest.
Public descriptions indicate tumor material/tumor digest can be cryopreserved prior to expansion, which does meet your CSM definition (no gene step, but it’s the starting cellular material).
This is a cleaner example of cryopreserved CSM in a marketed product.
Cord blood units (allogeneic HSC):
CSM = final product in practice; cord blood is collected and cryopreserved as banked units.
There is no gene introduction step; the “starting material” is cryopreserved and later used clinically.
If you accept non–gene‑modified cell therapies, these are canonical cryopreserved CSM.
4. Direct answer to your reframed question
Which FDA‑approved marketed cell‑based therapies use cryopreserved CSM (i.e., apheresis or analogous harvested cells/tissue) before gene introduction or ex vivo modification?
Based on what is explicitly supported in public regulatory and sponsor documentation:
For the six autologous CAR‑T products (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti):
We do not have solid public evidence that the licensed manufacturing processes require or routinely use cryopreserved CSM (apheresis) prior to gene introduction.
What is clearly documented is cryopreserved DS/DP, not cryopreserved CSM.
Clearer examples of cryopreserved CSM in marketed products are:
Amtagvi (lifileucel) – cryopreserved tumor/tumor digest as CSM prior to expansion.
Licensed cord blood units – cord blood collected and cryopreserved as the starting material for hematopoietic reconstitution (no gene step).
So under your stricter, CSM‑focused definition, the earlier claim that “all six CAR‑Ts use cryopreserved CSM” should be withdrawn. The defensible statement is:
All six CAR‑Ts use cryopreserved DS/DP; none can be confidently said—based on public regulatory documentation—to use cryopreserved CSM (apheresis) prior to gene introduction as part of the licensed process.
Can leukapheresis suppliers support a commercial process change to provide cryo-CSM?
Key to this learning exercise was to know that the AI is incorrect in some information provided. Now, we know Kymriah experienced process changes to include cryopreserved CSM in clinical trials with the goal to enable a global supply chain. A further prompt reveals this information as true:
Summarizing process changes
AI: I need to reanalyze process changes for six therapies, focusing on Kymriah's cryopreserved CSM. I already have key sources for Kymriah, like Tyagarajan Cytotherapy 2019 and Blood 2021 abstract. For the other therapies, there’s no clear evidence of a commercial process change to cryopreserved CSM, though there may be some feasibility studies or trials. I'll summarize the findings, define sources, and include five citations. I'll use Kymriah papers and maybe CARTITUDE, even though it’s not directly about CSM. Let’s get this organized! You’re asking exactly the right question now—not “is the product cryopreserved?” but “did the commercial process move to cryopreserved CSM (apheresis) pre‑gene‑modification, like Kymriah did?”
Here’s what I can support from public sources.
1. Sources and how I used them
Types of sources searched
Regulatory documents:
FDA/CBER prescribing information and BLAs/labels for all six products
Peer‑reviewed papers and short reports:
Manufacturing and process‑focused publications (e.g., Tyagarajan et al., Cytotherapy)
Conference abstracts/posters:
ASH/ASCO/Blood supplements on commercial manufacturing optimization
Sponsor/brand materials:
“Clinician’s guide” and process overviews where they explicitly describe leukapheresis handling
Reviews and mechanistic overviews:
Used only to cross‑check, not as primary evidence for process changes
Key Kymriah‑specific sources
Tyagarajan et al., Cytotherapy 2019:
“Tisagenlecleucel manufacturing uses cryopreserved leukapheresis as starting material.”
Rodrigues et al., Blood 2021 (ASH abstract “Optimizing Commercial Manufacturing of Tisagenlecleucel…”):
Describes commercial experience and explicitly notes use of cryopreserved leukapheresis starting material as a feature of the platform.
For the other products, I relied primarily on current US prescribing information and sponsor process descriptions; where those are silent on CSM cryopreservation, I did not infer a process change.
2. Kymriah (tisagenlecleucel) — evidence of cryopreserved CSM as a commercial process change
What changed
Early academic/clinical development used fresh leukapheresis as starting material.
Novartis subsequently adapted cryopreservation of leukapheresis into the industrial process to solve global supply‑chain/logistics constraints.
Evidence
Tyagarajan et al. (2019) explicitly:
“Tisagenlecleucel manufacturing uses cryopreserved leukapheresis as starting material… Cryopreservation was adapted into the Novartis manufacturing process from the beginning of clinical trials… to maximize manufacturing success rates and overcome logistical challenges.”
The same paper describes comparability work between fresh vs cryopreserved leukapheresis, optimization of hold times and temperatures, and concludes that the validated commercial process uses cryopreserved non‑mobilized PBMC leukapheresis as CSM.
The ASH 2021 “4‑year experiential journey” abstract on commercial manufacturing notes that use of cryopreserved leukapheresis starting material is a distinctive feature of tisagenlecleucel’s commercial process, enabling scheduling flexibility and global logistics.
Conclusion for Kymriah
There is clear, explicit public evidence that commercial tisagenlecleucel now uses cryopreserved leukapheresis as CSM—a process evolution relative to the earliest fresh‑material paradigm.
Under your strict definition, Kymriah is a documented example of an FDA‑approved product whose licensed commercial process uses cryopreserved CSM prior to gene introduction.
3. Yescarta (axicabtagene ciloleucel)
What the label and public docs say
FDA PI and public clinical reviews describe:
Autologous leukapheresis as starting material
Lymphodepleting chemo, then infusion of a cryopreserved cell suspension as DP
They do not explicitly state that leukapheresis is cryopreserved prior to manufacturing; the focus is on cryopreserved DP.
Process‑change evidence
I did not find sponsor‑authored papers or conference abstracts that clearly state a commercial switch to cryopreserved leukapheresis CSM analogous to Tyagarajan’s description for Kymriah.
Some general CAR‑T logistics papers discuss feasibility of frozen leukopaks, but they are not framed as Yescarta‑specific, licensed process changes.
Conclusion for Yescarta
DP is clearly cryopreserved.
There is no explicit public evidence that the commercial, licensed process now uses cryopreserved CSM (apheresis) pre‑gene‑modification.
Any such change, if it exists, is not clearly documented in the same way as for Kymriah.
4. Tecartus (brexucabtagene autoleucel)
What the label says
FDA PI: autologous leukapheresis as starting material; CAR‑T suspension for infusion as DP. Cryopreservation is clearly associated with the final product, not the apheresis.
Process‑change evidence
Public materials (label, MedlinePlus, professional monographs) describe the usual CAR‑T workflow but do not specify cryopreserved leukapheresis as a required or defining feature of the commercial process.
I did not find Tecartus‑specific manufacturing abstracts analogous to the Kymriah Tyagarajan/Rodrigues papers that explicitly call out cryopreserved CSM.
Conclusion for Tecartus
DP is cryopreserved;
There is no clear public documentation that the CSM (apheresis) is cryopreserved as part of a defined commercial process change.
5. Breyanzi (lisocabtagene maraleucel)
What the label and sponsor site say
FDA PI and BMS materials:
Autologous leukapheresis as starting material
Final product is a cryopreserved CD4/CD8 CAR‑T suspension in vials.
Again, the cryopreservation is clearly tied to DS/DP, not explicitly to the apheresis CSM.
Process‑change evidence
I did not identify Breyanzi‑specific publications that state a commercial switch to cryopreserved leukapheresis CSM.
Some platform‑level discussions of CD4/CD8 fractionation and vialed DP exist, but they don’t explicitly re‑characterize CSM as cryopreserved.
Conclusion for Breyanzi
Cryopreserved DS/DP is well documented.
No explicit public evidence that CSM is cryopreserved pre‑gene‑introduction as a defined commercial process change.
6. Abecma (idecabtagene vicleucel)
What the label and sponsor materials say
FDA PI: describes ABECMA as a cell suspension for IV infusion, with dosing based on CAR‑positive T cells; the product is supplied as a cryopreserved suspension.
The “Clinician’s Guide to ABECMA Cell Therapy Process” walks through leukapheresis, manufacturing, and infusion, but focuses on DP cryopreservation and logistics, not on freezing the leukapheresis itself.
Process‑change evidence
No public document I found states that commercial ABECMA now uses cryopreserved leukapheresis CSM as a defined process change.
As with others, feasibility of frozen leukopaks is discussed in the broader CAR‑T literature, but not as a labeled, ABECMA‑specific commercial change.
Conclusion for Abecma
DP is cryopreserved.
No explicit public evidence of a commercial process change to cryopreserved CSM.
7. Carvykti (ciltacabtagene autoleucel)
What the label and literature say
FDA PI: describes CARVYKTI as a cell suspension for IV infusion, with dosing based on CAR‑positive T cells; the product is supplied as a cryopreserved suspension.
Mechanistic/clinical reviews (e.g., Abebe et al., Front Immunol 2022) focus on construct design, efficacy, and safety; they do not detail a switch to cryopreserved leukapheresis CSM.
Process‑change evidence
I did not find any Carvykti‑specific abstract or poster that explicitly states “commercial process now uses cryopreserved leukapheresis as starting material.”
Conclusion for Carvykti
DP is cryopreserved.
No clear public documentation of cryopreserved CSM as a defined commercial process change.
8. Synthesis: where we do and don’t have evidence of cryopreserved CSM
Under your strict definition—CSM = apheresis (or analogous harvested cells/tissue) before gene introduction:
Kymriah (tisagenlecleucel)
Yes, documented cryopreserved CSM.
Peer‑reviewed and conference sources explicitly state that commercial manufacturing uses cryopreserved leukapheresis as starting material, with comparability and validation work to support that process.
Yescarta, Tecartus, Breyanzi, Abecma, Carvykti
All clearly use cryopreserved DS/DP.
I did not find public, product‑specific evidence that their licensed commercial processes have been updated to require or define cryopreserved CSM (apheresis) pre‑gene‑introduction.
Where the record is silent, the only defensible position is: “no documented cryopreserved CSM”, even though frozen leukopaks are technically feasible and may be used in some settings.
Can this be verified (or validated)?
One has to ask, why haven’t other cell therapies followed the cryopreserved CSM footsteps? Great question, I would say, and clearly I’m not the only one to have posited a few answers.
Let’s start with what is believed and what evidence we have to continue believing that:
Cryopreservation can only occur in hospital labs that process PHS 361 therapies.
Cryopreservation is as unique as the center performing the task.
Cryopreservation of CSM has untold effects on cell population recovery.
Cryopreservation of CSM has untold effects on cell processing (361)/manufacturing (351).
Cryopreservation of CSM has untold effects on cell populations post-transplant, affecting engraftment.
Cryopreservation process validation is only a concern for adhering to Biologics 351 GMP.
21CFR 1271 GTP combined with 21CFR 606, 630, and 640 (PHS361 blood/transfusion CFR) is not compatible with 21CFR 11, 210, 211, 312, 610, biologics-applicable 600-800’s (PHS351 Biologics CFR/GMP).
There is a lot of information out there that has already been said in conference halls and seminars throughout the last decade. AI can prove to be helpful to resurface and bring content to life, but can certainly get things wrong if not carefully guided. More to blog…
